Lupin Pharmaceuticals

Lupin Pharmaceuticals, Inc. is the U.S. operating subsidiary of Lupin Limited (also styled Lupin Ltd), an Indian transnational pharmaceutical company. Lupin Limited is headquartered in Mumbai, Maharashtra, India (Kalpataru Inspire, Santacruz East); the U.S. arm is based at Harborplace Tower, 111 S. Calvert Street, Baltimore, Maryland, with additional U.S. offices including Somerset, New Jersey. Lupin Limited was founded in 1968 (incorporated 1983) and is publicly listed on the National Stock Exchange of India under ticker LUPIN. Public sources put revenue around US$2.7 billion (FY2025) and headcount in the roughly 19,000–22,000 range, with market capitalization on the order of US$11 billion. Figures vary by source and fiscal year.

Operations. Lupin is an operating pharmaceutical manufacturer, not a patent-assertion entity. It develops, manufactures, and markets generic and branded-generic formulations, complex generics, active pharmaceutical ingredients (APIs), biosimilars, and specialty medicines, selling in roughly 100 countries. Major therapeutic areas include anti-tuberculosis, diabetes, cardiovascular, respiratory, ophthalmic, central nervous system, and women's health. Its biosimilars include Filgrastim, Pegfilgrastim, and Etanercept; diabetes brands include ONDERO. The company reports 15 manufacturing sites and seven research centers globally.

Patent-litigation posture. The structured data shows 0 cases as plaintiff and 1 as defendant — the profile of an operating company being sued, not an NPE. The single tracked matter is a Hatch-Waxman ANDA dispute in the U.S. District Court for the District of New Jersey, a common venue for generic/branded pharmaceutical patent cases (not a plaintiff-friendly NPE venue like the Eastern District of Texas). Lupin appears as a defendant rather than as an acquirer or asserter of patents.

Notable case. Jazz Pharmaceuticals, Inc. et al. v. Lupin Ltd. et al., D.N.J. Jazz Pharmaceuticals Ireland sued Lupin Ltd., Lupin Inc., and Lupin Pharmaceuticals, Inc. (alongside Teva) under 35 U.S.C. § 271(e)(2) after Lupin filed ANDA No. 215911 for a generic version of Jazz's Xywav (calcium/magnesium/potassium/sodium oxybate) oral solution, triggering Paragraph IV litigation over Jazz's oxybate composition and dosing patents. Lupin is a serial ANDA filer; such suits are routine for a generics manufacturer.